Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00158184 · ClinicalTrials.gov registry record · Phase 2

Prescription Opioid Effects in Abusers Versus Non-Abusers

A Phase 2 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
27
Enrollment target

NCT00158184 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00158184, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
27 participants
Enrollment target

Study Summary

The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.

Interventions

  • DRUG oxycodone 15 mg
  • DRUG oxycodone 30 mg
  • DRUG Placebo 0 mg

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2004-06
Est. Completion 2009-06
Phase Phase 2

What the Registry Record Tells You About NCT00158184

The ClinicalTrials.gov registry entry for NCT00158184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which oxycodone 15 mg is the first listed.

NCT00158184 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00158184 about?

NCT00158184 is a clinical study titled "Prescription Opioid Effects in Abusers Versus Non-Abusers". The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.

What is the current status of trial NCT00158184?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2004-06. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00158184?

The interventions under investigation include: oxycodone 15 mg (DRUG), oxycodone 30 mg (DRUG), Placebo 0 mg (DRUG).

Who is sponsoring clinical trial NCT00158184?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.